

control methods, and the slightly higher drug prices that may result in some instances, would be more than justified by the improvement in drug quality that would be achieved.

We have given careful consideration to proposals for the placement of fulltime Food and Drug Administration inspectors in every drug manufacturing plant--large and small--but believe this would involve unjustifiably heavy expenses and inappropriate use of skilled manpower.

We have also considered proposals for the extension of batch certification--now applied mainly for insulin, antibiotics and biologicals--to all drugs, requiring FDA testing and approval at the manufacturer's expense before any batch may be released for distribution. We feel this would place an unnecessarily heavy and costly burden on manufacturers which would be reflected in unnecessarily higher prices to consumers.

Instead, we find that further study is needed on the use of self-certification, with each manufacturer instituting and maintaining a quality certifying program approved by FDA.